Pemafibrate improved postprandial TG, Reml-C and ApoB48 in patients with type 2 diabetes (T2D) and hypertriglyceridemia: A post-hoc analysis of the phase 3 clinical trial

Saved in:
Bibliographic Details
Published inAtherosclerosis Vol. 355; p. 64
Main Authors Arai, H., Yamashita, S., Yokote, K., Araki, E., Hounslow, N., Ikeda, K., Nojima, T., Suganami, H., Ishibashi, S.
Format Journal Article
LanguageEnglish
Published Elsevier B.V 01.08.2022
Online AccessGet full text

Cover

More Information
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2022.06.418